Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canny Clozel Gets Another $230m From J&J For Idorsia Hypertension Drug

Executive Summary

Idorsia, the Swiss company spun out of Actelion after the latter was bought by J&J, is to get another windfall from the US major which has triggered an option to co-develop the Phase III-ready drug aprocitentan.

Advertisement

Related Content

Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Can Actelion Founder Clozel Recreate Another Top Biotech Post-J&J Sale?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100001

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel